{"abstracts-retrieval-response": {
    "item": {
        "ait:process-info": {
            "ait:status": {
                "@state": "update",
                "@type": "core",
                "@stage": "S300"
            },
            "ait:date-delivered": {
                "@day": "27",
                "@timestamp": "2023-07-27T10:04:51.000051-04:00",
                "@year": "2023",
                "@month": "07"
            },
            "ait:date-sort": {
                "@day": "01",
                "@year": "2023",
                "@month": "03"
            }
        },
        "xocs:meta": {"xocs:funding-list": {
            "@pui-match": "primary",
            "@has-funding-info": "1",
            "xocs:funding": [
                {
                    "xocs:funding-agency-matched-string": "GSK",
                    "xocs:funding-agency-acronym": "GSK",
                    "xocs:funding-agency": "GlaxoSmithKline",
                    "xocs:funding-agency-id": "http://data.elsevier.com/vocabulary/SciValFunders/100004330",
                    "xocs:funding-agency-country": "http://sws.geonames.org/2635167/"
                },
                {
                    "xocs:funding-agency-matched-string": "Gilead Sciences",
                    "xocs:funding-agency": "Gilead Sciences",
                    "xocs:funding-agency-id": "http://data.elsevier.com/vocabulary/SciValFunders/100005564",
                    "xocs:funding-agency-country": "http://sws.geonames.org/6252001/"
                },
                {
                    "xocs:funding-agency-matched-string": "MSD",
                    "xocs:funding-agency-acronym": "MSD",
                    "xocs:funding-agency": "Meso Scale Diagnostics",
                    "xocs:funding-agency-id": "http://data.elsevier.com/vocabulary/SciValFunders/100007054",
                    "xocs:funding-agency-country": "http://sws.geonames.org/6252001/"
                }
            ],
            "xocs:funding-addon-generated-timestamp": "2023-03-22T09:24:03.356Z",
            "xocs:funding-text": [
                {"$": "Anchalee Avihingsanon has received research grants from Gilead, MSD, Viatris, and GSK. Ploenchan Chetchotisakd has received research grants from Gilead, MSD, and GSK. Hal Martin, Hui Wang, TinHung Wong, and Hsiu Yin Wang are employees of Gilead Sciences. Sasisopin Kiertiburanakul, Winai Ratanasuwan, Krittaecho Siripassorn, and Khuanchai Supparatpinyo have no competing interests."},
                {"$": "This pooled analysis, as well as the parent phase III studies, was funded by Gilead Sciences."}
            ],
            "xocs:funding-addon-type": "http://vtw.elsevier.com/data/voc/AddOnTypes/50.7/aggregated-refined"
        }},
        "bibrecord": {
            "head": {
                "author-group": [
                    {
                        "affiliation": {
                            "country": "Thailand",
                            "@afid": "60016965",
                            "@country": "tha",
                            "city": "Bangkok",
                            "organization": [
                                {"$": "HIV-NAT"},
                                {"$": "Thai Red Cross AIDS Research Centre"}
                            ],
                            "affiliation-id": [
                                {"@afid": "60016965"},
                                {"@afid": "60031780"}
                            ],
                            "@affiliation-instance-id": "OB2BibRecID-942296673-03b414e37d862229b8b607b57af154d0-1",
                            "ce:source-text": "HIV-NAT, Thai Red Cross AIDS Research Centre, Bangkok, Thailand"
                        },
                        "author": [{
                            "ce:given-name": "Anchalee",
                            "preferred-name": {
                                "ce:given-name": "Anchalee",
                                "ce:initials": "A.",
                                "ce:surname": "Avihingsanon",
                                "ce:indexed-name": "Avihingsanon A."
                            },
                            "@author-instance-id": "OB2BibRecID-942296673-e5c8b57de4c21402221bbf12da4abe1c-1",
                            "@seq": "1",
                            "ce:initials": "A.",
                            "@date-locked": "2023-01-18T05:16:58.450",
                            "@_fa": "true",
                            "@type": "auth",
                            "ce:surname": "Avihingsanon",
                            "@auid": "57196347321",
                            "@orcid": "0000-0003-3222-9611",
                            "ce:indexed-name": "Avihingsanon A."
                        }]
                    },
                    {
                        "affiliation": {
                            "country": "Thailand",
                            "@afid": "60002620",
                            "@country": "tha",
                            "city": "Bangkok",
                            "organization": [
                                {"$": "Centre of Excellence in Tuberculosis"},
                                {"$": "Faculty of Medicine"},
                                {"$": "Chulalongkorn University"}
                            ],
                            "affiliation-id": [
                                {
                                    "@afid": "60002620",
                                    "@dptid": "127930232"
                                },
                                {"@afid": "60028190"}
                            ],
                            "@affiliation-instance-id": "OB2BibRecID-942296673-dd36a971dcf8dc41cf2f997deca66717-1",
                            "ce:source-text": "Centre of Excellence in Tuberculosis, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand",
                            "@dptid": "127930232"
                        },
                        "author": [{
                            "ce:given-name": "Anchalee",
                            "preferred-name": {
                                "ce:given-name": "Anchalee",
                                "ce:initials": "A.",
                                "ce:surname": "Avihingsanon",
                                "ce:indexed-name": "Avihingsanon A."
                            },
                            "@author-instance-id": "OB2BibRecID-942296673-cd07549d2611fb16989a344c78da11ca-1",
                            "@seq": "1",
                            "ce:initials": "A.",
                            "@date-locked": "2023-01-18T05:16:58.450",
                            "@_fa": "true",
                            "@type": "auth",
                            "ce:surname": "Avihingsanon",
                            "@auid": "57196347321",
                            "ce:indexed-name": "Avihingsanon A."
                        }]
                    },
                    {
                        "affiliation": {
                            "country": "Thailand",
                            "@afid": "60026046",
                            "@country": "tha",
                            "city": "Khon Kaen",
                            "organization": [
                                {"$": "Faculty of Medicine"},
                                {"$": "Khon Kaen University"}
                            ],
                            "affiliation-id": [
                                {"@afid": "60026046"},
                                {"@afid": "60017165"}
                            ],
                            "@affiliation-instance-id": "OB2BibRecID-942296673-4dee8879ebadbe0cabf6c76ffdb3cf48-1",
                            "ce:source-text": "Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand"
                        },
                        "author": [{
                            "ce:given-name": "Ploenchan",
                            "preferred-name": {
                                "ce:given-name": "Ploenchan",
                                "ce:initials": "P.",
                                "ce:surname": "Chetchotisakd",
                                "ce:indexed-name": "Chetchotisakd P."
                            },
                            "@author-instance-id": "OB2BibRecID-942296673-aa3a5ddeedb3bf32358d554c1277ebb9-1",
                            "@seq": "2",
                            "ce:initials": "P.",
                            "@date-locked": "2022-12-16T05:05:30.157",
                            "@_fa": "true",
                            "@type": "auth",
                            "ce:surname": "Chetchotisakd",
                            "@auid": "56992885200",
                            "ce:indexed-name": "Chetchotisakd P."
                        }]
                    },
                    {
                        "affiliation": {
                            "country": "Thailand",
                            "@afid": "60015887",
                            "@country": "tha",
                            "city": "Bangkok",
                            "organization": [
                                {"$": "Faculty of Medicine Ramathibodi Hospital"},
                                {"$": "Mahidol University"}
                            ],
                            "affiliation-id": [
                                {"@afid": "60015887"},
                                {"@afid": "60012718"}
                            ],
                            "@affiliation-instance-id": "OB2BibRecID-942296673-f88f964a5f36c25604b78fdb2848bd86-1",
                            "ce:source-text": "Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand"
                        },
                        "author": [{
                            "ce:given-name": "Sasisopin",
                            "preferred-name": {
                                "ce:given-name": "Sasisopin",
                                "ce:initials": "S.",
                                "ce:surname": "Kiertiburanakul",
                                "ce:indexed-name": "Kiertiburanakul S."
                            },
                            "@author-instance-id": "OB2BibRecID-942296673-b476ac826bf69e4bee88abeadd37decc-1",
                            "@seq": "3",
                            "ce:initials": "S.",
                            "@_fa": "true",
                            "@type": "auth",
                            "ce:surname": "Kiertiburanakul",
                            "@auid": "6506539792",
                            "@orcid": "0000-0003-4379-4704",
                            "ce:indexed-name": "Kiertiburanakul S."
                        }]
                    },
                    {
                        "affiliation": {
                            "country": "Thailand",
                            "@afid": "60199575",
                            "@country": "tha",
                            "city": "Bangkok",
                            "organization": [
                                {"$": "Faculty of Medicine Siriraj Hospital"},
                                {"$": "Mahidol University"}
                            ],
                            "affiliation-id": [
                                {
                                    "@afid": "60199575",
                                    "@dptid": "125771106"
                                },
                                {"@afid": "60012718"}
                            ],
                            "@affiliation-instance-id": "OB2BibRecID-942296673-8f693cb62a3f1dc4a779178545b423d5-1",
                            "ce:source-text": "Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand",
                            "@dptid": "125771106"
                        },
                        "author": [{
                            "ce:given-name": "Winai",
                            "preferred-name": {
                                "ce:given-name": "Winai",
                                "ce:initials": "W.",
                                "ce:surname": "Ratanasuwan",
                                "ce:indexed-name": "Ratanasuwan W."
                            },
                            "@author-instance-id": "OB2BibRecID-942296673-72eba440194f32dc6156b2bd8d3cdea3-1",
                            "@seq": "4",
                            "ce:initials": "W.",
                            "@_fa": "true",
                            "@type": "auth",
                            "ce:surname": "Ratanasuwan",
                            "@auid": "6602129968",
                            "ce:indexed-name": "Ratanasuwan W."
                        }]
                    },
                    {
                        "affiliation": {
                            "country": "Thailand",
                            "@afid": "106545448",
                            "@country": "tha",
                            "city": "Nonthaburi",
                            "organization": {"$": "Bamrasnaradura Infectious Diseases Institute"},
                            "affiliation-id": {"@afid": "106545448"},
                            "@affiliation-instance-id": "OB2BibRecID-942296673-11112217d0e26f38294daf9b0d3c32e2-1",
                            "ce:source-text": "Bamrasnaradura Infectious Diseases Institute, Nonthaburi, Thailand"
                        },
                        "author": [{
                            "ce:given-name": "Krittaecho",
                            "preferred-name": {
                                "ce:given-name": "Krittaecho",
                                "ce:initials": "K.",
                                "ce:surname": "Siripassorn",
                                "ce:indexed-name": "Siripassorn K."
                            },
                            "@author-instance-id": "OB2BibRecID-942296673-d9360a0738a54c2772cbc25fb143e1c7-1",
                            "@seq": "5",
                            "ce:initials": "K.",
                            "@_fa": "true",
                            "@type": "auth",
                            "ce:surname": "Siripassorn",
                            "@auid": "35559614900",
                            "ce:indexed-name": "Siripassorn K."
                        }]
                    },
                    {
                        "affiliation": {
                            "country": "Thailand",
                            "@afid": "60032250",
                            "@country": "tha",
                            "city": "Chiang Mai",
                            "organization": [
                                {"$": "Faculty of Medicine"},
                                {"$": "Chiang Mai University"}
                            ],
                            "affiliation-id": [
                                {"@afid": "60032250"},
                                {"@afid": "60000881"}
                            ],
                            "@affiliation-instance-id": "OB2BibRecID-942296673-c232fc5f8195d01defd5e62207f95f26-1",
                            "ce:source-text": "Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand"
                        },
                        "author": [{
                            "ce:given-name": "Khuanchai",
                            "preferred-name": {
                                "ce:given-name": "Khuanchai",
                                "ce:initials": "K.",
                                "ce:surname": "Supparatpinyo",
                                "ce:indexed-name": "Supparatpinyo K."
                            },
                            "@author-instance-id": "OB2BibRecID-942296673-5c87af5239f280c8ae0faa2ab1dc5b14-1",
                            "@seq": "6",
                            "ce:initials": "K.",
                            "@_fa": "true",
                            "@type": "auth",
                            "ce:surname": "Supparatpinyo",
                            "@auid": "6602542079",
                            "ce:indexed-name": "Supparatpinyo K."
                        }]
                    },
                    {
                        "affiliation": {
                            "country": "United States",
                            "@afid": "60002909",
                            "@country": "usa",
                            "city": "Foster City",
                            "organization": {"$": "Gilead Sciences"},
                            "affiliation-id": {"@afid": "60002909"},
                            "state": "CA",
                            "@affiliation-instance-id": "OB2BibRecID-942296673-2a715ae2394c301a618136993c450a0d-1",
                            "ce:source-text": "Gilead Sciences, Foster City, California, USA"
                        },
                        "author": [
                            {
                                "ce:given-name": "Hal",
                                "preferred-name": {
                                    "ce:given-name": "Hal",
                                    "ce:initials": "H.",
                                    "ce:surname": "Martin",
                                    "ce:indexed-name": "Martin H."
                                },
                                "@author-instance-id": "OB2BibRecID-942296673-809747c0b5cf5389a5e95be3dccc09e8-1",
                                "@seq": "7",
                                "ce:initials": "H.",
                                "@_fa": "true",
                                "@type": "auth",
                                "ce:surname": "Martin",
                                "@auid": "56173399700",
                                "ce:indexed-name": "Martin H."
                            },
                            {
                                "ce:given-name": "Hui",
                                "preferred-name": {
                                    "ce:given-name": "Hui",
                                    "ce:initials": "H.",
                                    "ce:surname": "Wang",
                                    "ce:indexed-name": "Wang H."
                                },
                                "@author-instance-id": "OB2BibRecID-942296673-1b5ad49ab84ecd05e7af2d630f22fd7f-1",
                                "@seq": "8",
                                "ce:initials": "H.",
                                "@_fa": "true",
                                "@type": "auth",
                                "ce:surname": "Wang",
                                "@auid": "57196428615",
                                "ce:indexed-name": "Wang H."
                            }
                        ]
                    },
                    {
                        "affiliation": {
                            "country": "Hong Kong",
                            "@afid": "122211284",
                            "@country": "hkg",
                            "organization": {"$": "Gilead Sciences"},
                            "affiliation-id": {"@afid": "122211284"},
                            "@affiliation-instance-id": "OB2BibRecID-942296673-a09ab7a09311750fb3d61731ef36e32b-1",
                            "ce:source-text": "Gilead Sciences, Hong Kong"
                        },
                        "author": [{
                            "ce:given-name": "TinHung",
                            "preferred-name": {
                                "ce:given-name": "Tin Hung",
                                "ce:initials": "T.H.",
                                "ce:surname": "Wong",
                                "ce:indexed-name": "Wong T.H."
                            },
                            "@author-instance-id": "OB2BibRecID-942296673-5e0d0cb6859d3cbd7166cac9e15d26b1-1",
                            "@seq": "9",
                            "ce:initials": "T.",
                            "@_fa": "true",
                            "@type": "auth",
                            "ce:surname": "Wong",
                            "@auid": "57269830800",
                            "ce:indexed-name": "Wong T."
                        }]
                    },
                    {
                        "affiliation": {
                            "country": "Taiwan",
                            "@afid": "128478852",
                            "@country": "twn",
                            "city": "Taipei",
                            "organization": {"$": "Gilead Sciences"},
                            "affiliation-id": {"@afid": "128478852"},
                            "@affiliation-instance-id": "OB2BibRecID-942296673-f818ecd88c9c2feacdf07bb2ac613951-1",
                            "ce:source-text": "Gilead Sciences, Taipei, Taiwan"
                        },
                        "author": [{
                            "ce:given-name": "Hsiu Yin",
                            "preferred-name": {
                                "ce:given-name": "Hsiu Yin",
                                "ce:initials": "H.Y.",
                                "ce:surname": "Wang",
                                "ce:indexed-name": "Wang H.Y."
                            },
                            "@author-instance-id": "OB2BibRecID-942296673-43433a0e183c8923d9c794a919f0993e-1",
                            "@seq": "10",
                            "ce:initials": "H.Y.",
                            "@_fa": "true",
                            "@type": "auth",
                            "ce:surname": "Wang",
                            "@auid": "57850377200",
                            "ce:indexed-name": "Wang H.Y."
                        }]
                    }
                ],
                "citation-title": "Efficacy and safety of switching to bictegravir, emtricitabine, and tenofovir alafenamide in virologically suppressed Asian adults living with HIV: A pooled analysis from three international phase III randomized trials",
                "abstracts": "© 2022 The Authors. HIV Medicine published by John Wiley & Sons Ltd on behalf of British HIV Association.Objectives: Data on switching to bictegravir, emtricitabine, and tenofovir alafenamide (B/F/TAF) in virologically suppressed Asian people living with HIV are limited. We performed a pooled analysis of virologically suppressed Asian participants from three international phase III trials to evaluate the efficacy and safety of switching to B/F/TAF. Methods: Virologically suppressed people living with HIV were randomized to switch to B/F/TAF or to stay on baseline regimens. The primary endpoint was the proportion of participants with plasma HIV-1 RNA ≥50 copies/ml at week 48. We analysed the incidence of adverse events (AEs), laboratory abnormalities, and changes in relevant tolerability parameters through 48 weeks. Results: Overall, 136 Asian participants were included. The proportions of participants with plasma HIV-1 RNA ≥50 copies/ml at week 48 were low in both arms (0% for B/F/TAF vs 1.4% for those who stayed on baseline regimens). Those who switched to B/F/TAF had virological suppression rates similar to those who stayed on baseline regimens (100% vs 95.9%, p = 0.2485), with no treatment-emergent resistance. Drug-related AEs occurred in three participants in each arm; none were serious. No participants discontinued the study drug because of AEs, and no deaths were observed. No significant differences were observed between the arms in the median changes in estimated glomerular filtration rate, body weight, and most lipid parameters. Switching from tenofovir disoproxil fumarate-containing regimens to B/F/TAF resulted in a significant decrease in tubular proteinuria compared with those who stayed on baseline regimens (p < 0.01). Conclusions: Virologically suppressed Asian people living with HIV who switched to B/F/TAF maintained 100% virological suppression at week 48, with no treatment-emergent drug resistance and safety profiles comparable to those seen in people who stayed on baseline regimens. Clinical Trial Number: ClinicalTrials.gov (NCT02603120, NCT02652624, and NCT02603107).",
                "correspondence": {
                    "affiliation": {
                        "country": "Taiwan",
                        "address-part": "Songren Road 32-1 and 36-1, Xinyi District",
                        "postal-code": "110",
                        "@country": "twn",
                        "city": "Taipei",
                        "@affiliation-instance-id": "OB2BibRecID-942296673-1da2f08349a855934cf23ce2b3dc582b-1",
                        "ce:source-text": "Songren Road 32-1 and 36-1, Xinyi District, Taipei, 110, Taiwan"
                    },
                    "person": {
                        "ce:given-name": "Hsiu Yin",
                        "@author-instance-id": "OB2BibRecID-942296673-1d5ebee37fb1507adab7ca1aa2ff825f-1",
                        "ce:initials": "H.Y.",
                        "ce:surname": "Wang",
                        "ce:indexed-name": "Wang H.Y."
                    }
                },
                "citation-info": {
                    "author-keywords": {"author-keyword": [
                        {
                            "$": "Asian",
                            "@xml:lang": "eng",
                            "@original": "y"
                        },
                        {
                            "$": "Bictegravir",
                            "@xml:lang": "eng",
                            "@original": "y"
                        },
                        {
                            "$": "HIV",
                            "@xml:lang": "eng",
                            "@original": "y"
                        },
                        {
                            "$": "regimen switch",
                            "@xml:lang": "eng",
                            "@original": "y"
                        },
                        {
                            "$": "safety",
                            "@xml:lang": "eng",
                            "@original": "y"
                        },
                        {
                            "$": "virologically suppressed",
                            "@xml:lang": "eng",
                            "@original": "y"
                        }
                    ]},
                    "citation-type": {"@code": "ar"},
                    "citation-language": {
                        "@language": "English",
                        "@xml:lang": "eng"
                    },
                    "abstract-language": {
                        "@language": "English",
                        "@xml:lang": "eng"
                    }
                },
                "source": {
                    "website": {"ce:e-address": {
                        "$": "http://onlinelibrary.wiley.com/journal/10.1111/(ISSN)1468-1293",
                        "@type": "email"
                    }},
                    "translated-sourcetitle": {
                        "$": "HIV Medicine",
                        "@xml:lang": "eng"
                    },
                    "volisspag": {
                        "voliss": {
                            "@volume": "24",
                            "@issue": "3"
                        },
                        "pagerange": {
                            "@first": "290",
                            "@last": "300"
                        }
                    },
                    "@type": "j",
                    "sourcetitle": "HIV Medicine",
                    "publicationdate": {
                        "month": "03",
                        "year": "2023",
                        "date-text": "March 2023",
                        "day": "01"
                    },
                    "codencode": "HMIEA",
                    "sourcetitle-abbrev": "HIV Med.",
                    "@country": "gbr",
                    "issn": [
                        {
                            "$": "14681293",
                            "@type": "electronic"
                        },
                        {
                            "$": "14642662",
                            "@type": "print"
                        }
                    ],
                    "publicationyear": {"@first": "2023"},
                    "publisher": {"publishername": "John Wiley and Sons Inc"},
                    "@srcid": "22307"
                },
                "enhancement": {
                    "classificationgroup": {"classifications": [
                        {
                            "@type": "EMCLASS",
                            "classification": [
                                {
                                    "classification-code": "17",
                                    "classification-description": "Public Health, Social Medicine and Epidemiology"
                                },
                                {
                                    "classification-code": "37",
                                    "classification-description": "Drug Literature Index"
                                },
                                {
                                    "classification-code": "38",
                                    "classification-description": "Adverse Reactions Titles"
                                },
                                {
                                    "classification-code": "4",
                                    "classification-description": "Microbiology: Bacteriology, Mycology, Parasitology and Virology"
                                }
                            ]
                        },
                        {
                            "@type": "ASJC",
                            "classification": [
                                {"$": "2719"},
                                {"$": "2725"},
                                {"$": "2736"}
                            ]
                        },
                        {
                            "@type": "SUBJABBR",
                            "classification": "MEDI"
                        }
                    ]},
                    "chemicalgroup": {"chemicals": [
                        {
                            "@source": "esbd",
                            "chemical": [
                                {
                                    "cas-registry-number": "1319715-09-7",
                                    "chemical-name": "abacavir plus dolutegravir plus lamivudine"
                                },
                                {
                                    "cas-registry-number": "852337-16-7",
                                    "chemical-name": "abacavir plus lamivudine"
                                },
                                {
                                    "cas-registry-number": [
                                        {"$": "9000-90-2"},
                                        {"$": "9000-92-4"},
                                        {"$": "9001-19-8"}
                                    ],
                                    "enzyme-commission-number": "EC 3.2.1.1",
                                    "chemical-name": "amylase"
                                },
                                {
                                    "cas-registry-number": [
                                        {"$": "198904-31-3"},
                                        {"$": "229975-97-7"}
                                    ],
                                    "chemical-name": "atazanavir"
                                },
                                {
                                    "cas-registry-number": "1430117-57-9",
                                    "chemical-name": "cobicistat plus elvitegravir plus emtricitabine plus tenofovir disoproxil"
                                },
                                {
                                    "cas-registry-number": [
                                        {"$": "206361-99-1"},
                                        {"$": "635728-49-3"}
                                    ],
                                    "chemical-name": "darunavir"
                                },
                                {
                                    "cas-registry-number": "731772-45-5",
                                    "chemical-name": "emtricitabine plus tenofovir disoproxil"
                                },
                                {
                                    "cas-registry-number": "66455-18-3",
                                    "chemical-name": "lipid"
                                },
                                {
                                    "cas-registry-number": [
                                        {"$": "22177-51-1"},
                                        {"$": "2922-28-3"},
                                        {"$": "73-24-5"}
                                    ],
                                    "chemical-name": "adenine"
                                },
                                {
                                    "cas-registry-number": [
                                        {"$": "1611493-60-7"},
                                        {"$": "1807988-02-8"}
                                    ],
                                    "chemical-name": "bictegravir"
                                },
                                {
                                    "cas-registry-number": [
                                        {"$": "137530-41-7"},
                                        {"$": "143491-54-7"},
                                        {"$": "143491-57-0"}
                                    ],
                                    "chemical-name": "emtricitabine"
                                },
                                {
                                    "cas-registry-number": "63231-63-0",
                                    "chemical-name": "RNA"
                                }
                            ]
                        },
                        {
                            "@source": "nlm",
                            "chemical": [
                                {"chemical-name": "Adenine"},
                                {"chemical-name": "Anti-HIV Agents"},
                                {"chemical-name": "bictegravir"},
                                {"chemical-name": "Emtricitabine"},
                                {"chemical-name": "Heterocyclic Compounds, 4 or More Rings"},
                                {"chemical-name": "RNA"}
                            ]
                        }
                    ]}
                },
                "grantlist": {
                    "@complete": "y",
                    "grant-text": {
                        "$": "The authors thank the participants, investigators, and study staff for participating in the phase III studies included in this pooled analysis. The authors acknowledge Ruilin Chen (Costello Medical, Singapore, sponsored by Gilead Sciences) for medical writing and editorial assistance in preparing this manuscript for publication, based on the authors' input and direction.",
                        "@xml:lang": "eng"
                    },
                    "grant": {
                        "grant-agency": {
                            "@iso-code": "usa",
                            "$": "Gilead Sciences"
                        },
                        "grant-agency-id": "100005564"
                    }
                }
            },
            "item-info": {
                "copyright": {
                    "$": "Copyright 2023 Elsevier B.V., All rights reserved.",
                    "@type": "Elsevier"
                },
                "external-source": "MEDLINE",
                "dbcollection": [
                    {"$": "EMBASE"},
                    {"$": "MEDL"},
                    {"$": "REAXYSCAR"},
                    {"$": "SCOPUS"},
                    {"$": "Scopusbase"}
                ],
                "history": {"date-created": {
                    "@day": "01",
                    "@timestamp": "BST 03:29:19",
                    "@year": "2023",
                    "@month": "04"
                }},
                "itemidlist": {
                    "itemid": [
                        {
                            "$": "2018672838",
                            "@idtype": "PUI"
                        },
                        {
                            "$": "942296673",
                            "@idtype": "CAR-ID"
                        },
                        {
                            "$": "20220752600",
                            "@idtype": "EMBASE"
                        },
                        {
                            "$": "36912172",
                            "@idtype": "MEDL"
                        },
                        {
                            "$": "20222472686",
                            "@idtype": "REAXYSCAR"
                        },
                        {
                            "$": "20222884264",
                            "@idtype": "SCOPUS"
                        },
                        {
                            "$": "20229018715993",
                            "@idtype": "TPA-ID"
                        },
                        {
                            "$": "85136240517",
                            "@idtype": "SCP"
                        },
                        {
                            "$": "85136240517",
                            "@idtype": "SGR"
                        },
                        {
                            "$": "640577274",
                            "@idtype": "PUIsecondary"
                        },
                        {
                            "$": "77815599",
                            "@idtype": "OSIN"
                        }
                    ],
                    "ce:doi": "10.1111/hiv.13386"
                }
            },
            "tail": {"bibliography": {
                "@refcount": "34",
                "reference": [
                    {
                        "ref-fulltext": "Deeks ED. Bictegravir/emtricitabine/tenofovir alafenamide: a review in HIV-1 infection. Drugs. 2018;78(17):1817-1828.",
                        "@reference-instance-id": "OB2BibRecID-942296673-169a14bc977cf2a455981dd2104dc546-1",
                        "@id": "1",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2018"},
                            "ref-title": {"ref-titletext": "Bictegravir/emtricitabine/tenofovir alafenamide: a review in HIV-1 infection"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "hiv13386-cit-0001",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85057063883",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "78",
                                    "@issue": "17"
                                },
                                "pagerange": {
                                    "@first": "1817",
                                    "@last": "1828"
                                }
                            },
                            "ref-authors": {"author": [{
                                "@seq": "1",
                                "ce:initials": "E.D.",
                                "@_fa": "true",
                                "ce:surname": "Deeks",
                                "ce:indexed-name": "Deeks E.D."
                            }]},
                            "ref-sourcetitle": "Drugs"
                        },
                        "ce:source-text": "Deeks ED. Bictegravir/emtricitabine/tenofovir alafenamide: a review in HIV-1 infection. Drugs. 2018;78(17):1817-1828."
                    },
                    {
                        "ref-fulltext": "Sax PE, Pozniak A, Montes ML, et al. Coformulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection (GS-US-380\u20131490): a randomised, double-blind, multicentre, phase 3, non-inferiority trial. Lancet. 2017;390(10107):2073-2082.",
                        "@reference-instance-id": "OB2BibRecID-942296673-74598e6f83c6906d39d48c62daca97c2-2",
                        "@id": "2",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2017"},
                            "ref-title": {"ref-titletext": "Coformulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection (GS-US-380\u20131490): a randomised, double-blind, multicentre, phase 3, non-inferiority trial"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "hiv13386-cit-0002",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85028684793",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "390",
                                    "@issue": "10107"
                                },
                                "pagerange": {
                                    "@first": "2073",
                                    "@last": "2082"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "P.E.",
                                        "@_fa": "true",
                                        "ce:surname": "Sax",
                                        "ce:indexed-name": "Sax P.E."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "A.",
                                        "@_fa": "true",
                                        "ce:surname": "Pozniak",
                                        "ce:indexed-name": "Pozniak A."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "M.L.",
                                        "@_fa": "true",
                                        "ce:surname": "Montes",
                                        "ce:indexed-name": "Montes M.L."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Lancet"
                        },
                        "ce:source-text": "Sax PE, Pozniak A, Montes ML, et al. Coformulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection (GS-US-380\u20131490): a randomised, double-blind, multicentre, phase 3, non-inferiority trial. Lancet. 2017;390(10107):2073-2082."
                    },
                    {
                        "ref-fulltext": "EACS. Guidelines version 10.1. European AIDS Clinical Society; 2020.",
                        "@reference-instance-id": "OB2BibRecID-942296673-3ab9415849f0eeabb7f7d7ebba70d61f-3",
                        "@id": "3",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2020"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "hiv13386-cit-0003",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85111507319",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-text": "European AIDS Clinical Society",
                            "ref-authors": {"collaboration": {
                                "@seq": "1",
                                "ce:text": "EACS",
                                "ce:indexed-name": "EACS"
                            }},
                            "ref-sourcetitle": "Guidelines version 10.1"
                        },
                        "ce:source-text": "EACS. Guidelines version 10.1. European AIDS Clinical Society; 2020."
                    },
                    {
                        "ref-fulltext": "Saag MS, Gandhi RT, Hoy JF, et al. Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2020 recommendations of the international antiviral society\u2013USA panel. JAMA. 2020;324(16):1651-1669.",
                        "@reference-instance-id": "OB2BibRecID-942296673-c823637dc3f173a2c3d38c6918aeac21-4",
                        "@id": "4",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2020"},
                            "ref-title": {"ref-titletext": "Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2020 recommendations of the international antiviral society\u2013USA panel"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "hiv13386-cit-0004",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85094191925",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "324",
                                    "@issue": "16"
                                },
                                "pagerange": {
                                    "@first": "1651",
                                    "@last": "1669"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "M.S.",
                                        "@_fa": "true",
                                        "ce:surname": "Saag",
                                        "ce:indexed-name": "Saag M.S."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "R.T.",
                                        "@_fa": "true",
                                        "ce:surname": "Gandhi",
                                        "ce:indexed-name": "Gandhi R.T."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "J.F.",
                                        "@_fa": "true",
                                        "ce:surname": "Hoy",
                                        "ce:indexed-name": "Hoy J.F."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "JAMA"
                        },
                        "ce:source-text": "Saag MS, Gandhi RT, Hoy JF, et al. Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2020 recommendations of the international antiviral society\u2013USA panel. JAMA. 2020;324(16):1651-1669."
                    },
                    {
                        "ref-fulltext": "Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in adults and adolescents with HIV 2021;Available from: http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf.",
                        "@reference-instance-id": "OB2BibRecID-942296673-5cf35ea679c8637f4b3b47b308708db9-5",
                        "@id": "5",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2021"},
                            "ref-website": {"ce:e-address": {
                                "$": "http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf",
                                "@type": "email"
                            }},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "hiv13386-cit-0005",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "1442349426",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-text": "Available from",
                            "ref-authors": {"collaboration": {
                                "@seq": "1",
                                "ce:text": "Panel on Antiretroviral Guidelines for Adults and Adolescents",
                                "ce:indexed-name": "Panel on Antiretroviral Guidelines for Adults and Adolescents"
                            }},
                            "ref-sourcetitle": "Guidelines for the use of antiretroviral agents in adults and adolescents with HIV"
                        },
                        "ce:source-text": "Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in adults and adolescents with HIV 2021;Available from: http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf."
                    },
                    {
                        "ref-fulltext": "New data show switching to Biktarvy regimen beneficial in Asian population. 2020 Available from: https://www.thepharmaletter.com/article/new-data-show-switching-to-biktarvy-regimen-beneficial-in-asian-population.",
                        "@reference-instance-id": "OB2BibRecID-942296673-ef2d4fe95495bcbd167e2674a439f4ea-6",
                        "@id": "6",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2020"},
                            "ref-website": {"ce:e-address": {
                                "$": "https://www.thepharmaletter.com/article/new-data-show-switching-to-biktarvy-regimen-beneficial-in-asian-population",
                                "@type": "email"
                            }},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "hiv13386-cit-0006",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85136209604",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-text": "Available from",
                            "ref-authors": {"collaboration": {
                                "@seq": "1",
                                "ce:text": "New data show switching to Biktarvy regimen beneficial in Asian population",
                                "ce:indexed-name": "New data show switching to Biktarvy regimen beneficial in Asian population"
                            }}
                        },
                        "ce:source-text": "New data show switching to Biktarvy regimen beneficial in Asian population. 2020 Available from: https://www.thepharmaletter.com/article/new-data-show-switching-to-biktarvy-regimen-beneficial-in-asian-population."
                    },
                    {
                        "ref-fulltext": "Taiwan AIDS Society. Guidelines for the Diagnosis and Treatment of AIDS 2020.",
                        "@reference-instance-id": "OB2BibRecID-942296673-729c9ed27dd97e3bfd634aef25f7b203-7",
                        "@id": "7",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2020"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "hiv13386-cit-0007",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85084053016",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-authors": {"collaboration": {
                                "@seq": "1",
                                "ce:text": "Taiwan AIDS Society",
                                "ce:indexed-name": "Taiwan AIDS Society"
                            }},
                            "ref-sourcetitle": "Guidelines for the Diagnosis and Treatment of AIDS"
                        },
                        "ce:source-text": "Taiwan AIDS Society. Guidelines for the Diagnosis and Treatment of AIDS 2020."
                    },
                    {
                        "ref-fulltext": "UNAIDS. Regional factsheets: Asia and Pacific 2020. 2021. Available from: https://aidsinfo.unaids.org/.",
                        "@reference-instance-id": "OB2BibRecID-942296673-25fb8288f6fceb81b113c313e22b04f4-8",
                        "@id": "8",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2021"},
                            "ref-website": {"ce:e-address": {
                                "$": "https://aidsinfo.unaids.org/",
                                "@type": "email"
                            }},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "hiv13386-cit-0008",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85136177485",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-text": "Available from",
                            "ref-authors": {"collaboration": {
                                "@seq": "1",
                                "ce:text": "UNAIDS",
                                "ce:indexed-name": "UNAIDS"
                            }},
                            "ref-sourcetitle": "Regional factsheets: Asia and Pacific 2020"
                        },
                        "ce:source-text": "UNAIDS. Regional factsheets: Asia and Pacific 2020. 2021. Available from: https://aidsinfo.unaids.org/."
                    },
                    {
                        "ref-fulltext": "World Health Organization. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection 2016.",
                        "@reference-instance-id": "OB2BibRecID-942296673-08b45d8fc307f454f3e8236144bfa1f9-9",
                        "@id": "9",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2016"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "hiv13386-cit-0009",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "84979639164",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-authors": {"collaboration": {
                                "@seq": "1",
                                "ce:text": "World Health Organization",
                                "ce:indexed-name": "World Health Organization"
                            }},
                            "ref-sourcetitle": "Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection"
                        },
                        "ce:source-text": "World Health Organization. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection 2016."
                    },
                    {
                        "ref-fulltext": "Chinese guidelines for diagnosis and treatment of HIV/AIDS. Zhonghua Nei Ke Za Zhi. Chin J Intern Med. 2018;57(12):867-884.",
                        "@reference-instance-id": "OB2BibRecID-942296673-9aa8617fcc589310f5f95f56ca82b9d5-10",
                        "@id": "10",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2018"},
                            "ref-title": {"ref-titletext": "Zhonghua Nei Ke Za Zhi"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "hiv13386-cit-0010",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85067672724",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "57",
                                    "@issue": "12"
                                },
                                "pagerange": {
                                    "@first": "867",
                                    "@last": "884"
                                }
                            },
                            "ref-authors": {"collaboration": {
                                "@seq": "1",
                                "ce:text": "Chinese guidelines for diagnosis and treatment of HIV/AIDS",
                                "ce:indexed-name": "Chinese guidelines for diagnosis and treatment of HIV/AIDS"
                            }},
                            "ref-sourcetitle": "Chin J Intern Med"
                        },
                        "ce:source-text": "Chinese guidelines for diagnosis and treatment of HIV/AIDS. Zhonghua Nei Ke Za Zhi. Chin J Intern Med. 2018;57(12):867-884."
                    },
                    {
                        "ref-fulltext": "Gallant J, Lazzarin A, Mills A, et al. Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial. Lancet. 2017;390(10107):2063-2072.",
                        "@reference-instance-id": "OB2BibRecID-942296673-96768f2f802d48388e5a74291980b436-11",
                        "@id": "11",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2017"},
                            "ref-title": {"ref-titletext": "Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "hiv13386-cit-0011",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85028623606",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "390",
                                    "@issue": "10107"
                                },
                                "pagerange": {
                                    "@first": "2063",
                                    "@last": "2072"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "J.",
                                        "@_fa": "true",
                                        "ce:surname": "Gallant",
                                        "ce:indexed-name": "Gallant J."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "A.",
                                        "@_fa": "true",
                                        "ce:surname": "Lazzarin",
                                        "ce:indexed-name": "Lazzarin A."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "A.",
                                        "@_fa": "true",
                                        "ce:surname": "Mills",
                                        "ce:indexed-name": "Mills A."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Lancet"
                        },
                        "ce:source-text": "Gallant J, Lazzarin A, Mills A, et al. Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial. Lancet. 2017;390(10107):2063-2072."
                    },
                    {
                        "ref-fulltext": "Wohl DA, Yazdanpanah Y, Baumgarten A, et al. Bictegravir combined with emtricitabine and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trial. Lancet HIV. 2019;6(6):e355-e363.",
                        "@reference-instance-id": "OB2BibRecID-942296673-ab8fb3b66a936d36175c2c12660b9ca6-12",
                        "@id": "12",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2019"},
                            "ref-title": {"ref-titletext": "Bictegravir combined with emtricitabine and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trial"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "hiv13386-cit-0012",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85066295031",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "6",
                                    "@issue": "6"
                                },
                                "pagerange": {
                                    "@first": "e355",
                                    "@last": "e363"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "D.A.",
                                        "@_fa": "true",
                                        "ce:surname": "Wohl",
                                        "ce:indexed-name": "Wohl D.A."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "Y.",
                                        "@_fa": "true",
                                        "ce:surname": "Yazdanpanah",
                                        "ce:indexed-name": "Yazdanpanah Y."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "A.",
                                        "@_fa": "true",
                                        "ce:surname": "Baumgarten",
                                        "ce:indexed-name": "Baumgarten A."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Lancet HIV"
                        },
                        "ce:source-text": "Wohl DA, Yazdanpanah Y, Baumgarten A, et al. Bictegravir combined with emtricitabine and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trial. Lancet HIV. 2019;6(6):e355-e363."
                    },
                    {
                        "ref-fulltext": "Orkin C, DeJesus E, Sax PE, et al. Fixed-dose combination bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir-containing regimens for initial treatment of HIV-1 infection: week 144 results from two randomised, double-blind, multicentre, phase 3, non-inferiority trials. Lancet HIV. 2020;7(6):e389-e400.",
                        "@reference-instance-id": "OB2BibRecID-942296673-e26e2cdcbc58e33b9e3c21ddd2e03ddf-13",
                        "@id": "13",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2020"},
                            "ref-title": {"ref-titletext": "Fixed-dose combination bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir-containing regimens for initial treatment of HIV-1 infection: week 144 results from two randomised, double-blind, multicentre, phase 3, non-inferiority trials"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "hiv13386-cit-0013",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85085644946",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "7",
                                    "@issue": "6"
                                },
                                "pagerange": {
                                    "@first": "e389",
                                    "@last": "e400"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "C.",
                                        "@_fa": "true",
                                        "ce:surname": "Orkin",
                                        "ce:indexed-name": "Orkin C."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "E.",
                                        "@_fa": "true",
                                        "ce:surname": "DeJesus",
                                        "ce:indexed-name": "DeJesus E."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "P.E.",
                                        "@_fa": "true",
                                        "ce:surname": "Sax",
                                        "ce:indexed-name": "Sax P.E."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Lancet HIV"
                        },
                        "ce:source-text": "Orkin C, DeJesus E, Sax PE, et al. Fixed-dose combination bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir-containing regimens for initial treatment of HIV-1 infection: week 144 results from two randomised, double-blind, multicentre, phase 3, non-inferiority trials. Lancet HIV. 2020;7(6):e389-e400."
                    },
                    {
                        "ref-fulltext": "Stellbrink H-J, Arribas JR, Stephens JL, et al. Co-formulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trial. Lancet HIV. 2019;6(6):e364-e372.",
                        "@reference-instance-id": "OB2BibRecID-942296673-afbe0569cd6c25279ba7de45a701e0ae-14",
                        "@id": "14",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2019"},
                            "ref-title": {"ref-titletext": "Co-formulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trial"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "hiv13386-cit-0014",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85066237687",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "6",
                                    "@issue": "6"
                                },
                                "pagerange": {
                                    "@first": "e364",
                                    "@last": "e372"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "H.-J.",
                                        "@_fa": "true",
                                        "ce:surname": "Stellbrink",
                                        "ce:indexed-name": "Stellbrink H.-J."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "J.R.",
                                        "@_fa": "true",
                                        "ce:surname": "Arribas",
                                        "ce:indexed-name": "Arribas J.R."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "J.L.",
                                        "@_fa": "true",
                                        "ce:surname": "Stephens",
                                        "ce:indexed-name": "Stephens J.L."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Lancet HIV"
                        },
                        "ce:source-text": "Stellbrink H-J, Arribas JR, Stephens JL, et al. Co-formulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trial. Lancet HIV. 2019;6(6):e364-e372."
                    },
                    {
                        "ref-fulltext": "Molina J-M, Ward D, Brar I, et al. Switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from dolutegravir plus abacavir and lamivudine in virologically suppressed adults with HIV-1: 48 week results of a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial. Lancet HIV. 2018;5(7):e357-e365.",
                        "@reference-instance-id": "OB2BibRecID-942296673-b0161bb9764eb2e9c77ade4e5444cde2-15",
                        "@id": "15",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2018"},
                            "ref-title": {"ref-titletext": "Switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from dolutegravir plus abacavir and lamivudine in virologically suppressed adults with HIV-1: 48 week results of a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "hiv13386-cit-0015",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85048543569",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "5",
                                    "@issue": "7"
                                },
                                "pagerange": {
                                    "@first": "e357",
                                    "@last": "e365"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "J.-M.",
                                        "@_fa": "true",
                                        "ce:surname": "Molina",
                                        "ce:indexed-name": "Molina J.-M."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "D.",
                                        "@_fa": "true",
                                        "ce:surname": "Ward",
                                        "ce:indexed-name": "Ward D."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "I.",
                                        "@_fa": "true",
                                        "ce:surname": "Brar",
                                        "ce:indexed-name": "Brar I."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Lancet HIV"
                        },
                        "ce:source-text": "Molina J-M, Ward D, Brar I, et al. Switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from dolutegravir plus abacavir and lamivudine in virologically suppressed adults with HIV-1: 48 week results of a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial. Lancet HIV. 2018;5(7):e357-e365."
                    },
                    {
                        "ref-fulltext": "Kityo C, Hagins D, Koenig E, et al. Switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide (B/F/TAF) in virologically suppressed HIV-1 infected women: a randomized, open-label, multicenter, active-controlled, phase 3, noninferiority trial. J Acquir Immune Defic Syndr. 2019;82(3):321-328.",
                        "@reference-instance-id": "OB2BibRecID-942296673-cc0cc60eea396be96aab0c2b9ad5f4f7-16",
                        "@id": "16",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2019"},
                            "ref-title": {"ref-titletext": "Switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide (B/F/TAF) in virologically suppressed HIV-1 infected women: a randomized, open-label, multicenter, active-controlled, phase 3, noninferiority trial"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "hiv13386-cit-0016",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85073178758",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "82",
                                    "@issue": "3"
                                },
                                "pagerange": {
                                    "@first": "321",
                                    "@last": "328"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "C.",
                                        "@_fa": "true",
                                        "ce:surname": "Kityo",
                                        "ce:indexed-name": "Kityo C."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "D.",
                                        "@_fa": "true",
                                        "ce:surname": "Hagins",
                                        "ce:indexed-name": "Hagins D."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "E.",
                                        "@_fa": "true",
                                        "ce:surname": "Koenig",
                                        "ce:indexed-name": "Koenig E."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "J Acquir Immune Defic Syndr"
                        },
                        "ce:source-text": "Kityo C, Hagins D, Koenig E, et al. Switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide (B/F/TAF) in virologically suppressed HIV-1 infected women: a randomized, open-label, multicenter, active-controlled, phase 3, noninferiority trial. J Acquir Immune Defic Syndr. 2019;82(3):321-328."
                    },
                    {
                        "ref-fulltext": "Daar ES, DeJesus E, Ruane P, et al. Efficacy and safety of switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from boosted protease inhibitor-based regimens in virologically suppressed adults with HIV-1: 48 week results of a randomised, open-label, multicentre, phase 3, non-inferiority trial. Lancet HIV. 2018;5(7):e347-e356.",
                        "@reference-instance-id": "OB2BibRecID-942296673-62f78095d14b0fae79bdfd09f23b7915-17",
                        "@id": "17",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2018"},
                            "ref-title": {"ref-titletext": "Efficacy and safety of switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from boosted protease inhibitor-based regimens in virologically suppressed adults with HIV-1: 48 week results of a randomised, open-label, multicentre, phase 3, non-inferiority trial"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "hiv13386-cit-0017",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85048569792",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "5",
                                    "@issue": "7"
                                },
                                "pagerange": {
                                    "@first": "e347",
                                    "@last": "e356"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "E.S.",
                                        "@_fa": "true",
                                        "ce:surname": "Daar",
                                        "ce:indexed-name": "Daar E.S."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "E.",
                                        "@_fa": "true",
                                        "ce:surname": "DeJesus",
                                        "ce:indexed-name": "DeJesus E."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "P.",
                                        "@_fa": "true",
                                        "ce:surname": "Ruane",
                                        "ce:indexed-name": "Ruane P."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Lancet HIV"
                        },
                        "ce:source-text": "Daar ES, DeJesus E, Ruane P, et al. Efficacy and safety of switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from boosted protease inhibitor-based regimens in virologically suppressed adults with HIV-1: 48 week results of a randomised, open-label, multicentre, phase 3, non-inferiority trial. Lancet HIV. 2018;5(7):e347-e356."
                    },
                    {
                        "ref-fulltext": "Nishijima T, Komatsu H, Gatanaga H, et al. Impact of small body weight on Tenofovir-associated renal dysfunction in HIV-infected patients: a retrospective cohort study of Japanese patients. PLOS One. 2011;6(7):e22661.",
                        "@reference-instance-id": "OB2BibRecID-942296673-716e667f78a4544f36c1179988b2b313-18",
                        "@id": "18",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2011"},
                            "ref-title": {"ref-titletext": "Impact of small body weight on Tenofovir-associated renal dysfunction in HIV-infected patients: a retrospective cohort study of Japanese patients"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "hiv13386-cit-0018",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "79960725563",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {"voliss": {
                                "@volume": "6",
                                "@issue": "7"
                            }},
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "T.",
                                        "@_fa": "true",
                                        "ce:surname": "Nishijima",
                                        "ce:indexed-name": "Nishijima T."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "H.",
                                        "@_fa": "true",
                                        "ce:surname": "Komatsu",
                                        "ce:indexed-name": "Komatsu H."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "H.",
                                        "@_fa": "true",
                                        "ce:surname": "Gatanaga",
                                        "ce:indexed-name": "Gatanaga H."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "PLOS One"
                        },
                        "ce:source-text": "Nishijima T, Komatsu H, Gatanaga H, et al. Impact of small body weight on Tenofovir-associated renal dysfunction in HIV-infected patients: a retrospective cohort study of Japanese patients. PLOS One. 2011;6(7):e22661."
                    },
                    {
                        "ref-fulltext": "Nishijima T, Kawasaki Y, Tanaka N, et al. Long-term exposure to tenofovir continuously decrease renal function in HIV-1-infected patients with low body weight: results from 10 years of follow-up. AIDS. 2014;28(13):1903-1910.",
                        "@reference-instance-id": "OB2BibRecID-942296673-26d2f6a6ffb66d71f4f730b31478f3d3-19",
                        "@id": "19",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2014"},
                            "ref-title": {"ref-titletext": "Long-term exposure to tenofovir continuously decrease renal function in HIV-1-infected patients with low body weight: results from 10 years of follow-up"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "hiv13386-cit-0019",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "84906536813",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "28",
                                    "@issue": "13"
                                },
                                "pagerange": {
                                    "@first": "1903",
                                    "@last": "1910"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "T.",
                                        "@_fa": "true",
                                        "ce:surname": "Nishijima",
                                        "ce:indexed-name": "Nishijima T."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "Y.",
                                        "@_fa": "true",
                                        "ce:surname": "Kawasaki",
                                        "ce:indexed-name": "Kawasaki Y."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "N.",
                                        "@_fa": "true",
                                        "ce:surname": "Tanaka",
                                        "ce:indexed-name": "Tanaka N."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "AIDS"
                        },
                        "ce:source-text": "Nishijima T, Kawasaki Y, Tanaka N, et al. Long-term exposure to tenofovir continuously decrease renal function in HIV-1-infected patients with low body weight: results from 10 years of follow-up. AIDS. 2014;28(13):1903-1910."
                    },
                    {
                        "ref-fulltext": "Mizushima D, Tanuma J, Dung NT, et al. Low body weight and tenofovir use are risk factors for renal dysfunction in Vietnamese HIV-infected patients. A prospective 18-month observation study. J Infect Chemother. 2014;20(12):784-788.",
                        "@reference-instance-id": "OB2BibRecID-942296673-031c56d652a4ac33440e4d3af26c726e-20",
                        "@id": "20",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2014"},
                            "ref-title": {"ref-titletext": "Low body weight and tenofovir use are risk factors for renal dysfunction in Vietnamese HIV-infected patients. A prospective 18-month observation study"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "hiv13386-cit-0020",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "84940997251",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "20",
                                    "@issue": "12"
                                },
                                "pagerange": {
                                    "@first": "784",
                                    "@last": "788"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "D.",
                                        "@_fa": "true",
                                        "ce:surname": "Mizushima",
                                        "ce:indexed-name": "Mizushima D."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "J.",
                                        "@_fa": "true",
                                        "ce:surname": "Tanuma",
                                        "ce:indexed-name": "Tanuma J."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "N.T.",
                                        "@_fa": "true",
                                        "ce:surname": "Dung",
                                        "ce:indexed-name": "Dung N.T."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "J Infect Chemother"
                        },
                        "ce:source-text": "Mizushima D, Tanuma J, Dung NT, et al. Low body weight and tenofovir use are risk factors for renal dysfunction in Vietnamese HIV-infected patients. A prospective 18-month observation study. J Infect Chemother. 2014;20(12):784-788."
                    },
                    {
                        "ref-fulltext": "ClinicalTrials.gov. Identifier NCT02603120, Safety and Efficacy of Switching From Dolutegravir and ABC/3TC or ABC/DTG/3TC to B/F/TAF in HIV-1 Infected Adults Who Are Virologically Suppressed 2020. Available from: https://clinicaltrials.gov/ct2/show/NCT02603120.",
                        "@reference-instance-id": "OB2BibRecID-942296673-e922f51006062e4b0bae18c38e4d1102-21",
                        "@id": "21",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2020"},
                            "ref-website": {"ce:e-address": {
                                "$": "https://clinicaltrials.gov/ct2/show/NCT02603120",
                                "@type": "email"
                            }},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "hiv13386-cit-0021",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85136189285",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-text": "Available from",
                            "ref-authors": {"collaboration": {
                                "@seq": "1",
                                "ce:text": "ClinicalTrials.gov",
                                "ce:indexed-name": "ClinicalTrials.gov"
                            }},
                            "ref-sourcetitle": "Identifier NCT02603120, Safety and Efficacy of Switching From Dolutegravir and ABC/3TC or ABC/DTG/3TC to B/F/TAF in HIV-1 Infected Adults Who Are Virologically Suppressed"
                        },
                        "ce:source-text": "ClinicalTrials.gov. Identifier NCT02603120, Safety and Efficacy of Switching From Dolutegravir and ABC/3TC or ABC/DTG/3TC to B/F/TAF in HIV-1 Infected Adults Who Are Virologically Suppressed 2020. Available from: https://clinicaltrials.gov/ct2/show/NCT02603120."
                    },
                    {
                        "ref-fulltext": "ClinicalTrials.gov. Identifier NCT02652624, Safety and Efficacy of Switching to a FDC of B/F/TAF From E/C/F/TAF, E/C/F/TDF, or ATV+RTV+FTC/TDF in Virologically Suppressed HIV-1 Infected Women 2020. Available from: https://clinicaltrials.gov/ct2/show/NCT02652624.",
                        "@reference-instance-id": "OB2BibRecID-942296673-beb0b73fad881f5eded43d7ce1dad432-22",
                        "@id": "22",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2020"},
                            "ref-website": {"ce:e-address": {
                                "$": "https://clinicaltrials.gov/ct2/show/NCT02652624",
                                "@type": "email"
                            }},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "hiv13386-cit-0022",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85136199054",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-text": "Available from",
                            "ref-authors": {"collaboration": {
                                "@seq": "1",
                                "ce:text": "ClinicalTrials.gov",
                                "ce:indexed-name": "ClinicalTrials.gov"
                            }},
                            "ref-sourcetitle": "Identifier NCT02652624, Safety and Efficacy of Switching to a FDC of B/F/TAF From E/C/F/TAF, E/C/F/TDF, or ATV+RTV+FTC/TDF in Virologically Suppressed HIV-1 Infected Women"
                        },
                        "ce:source-text": "ClinicalTrials.gov. Identifier NCT02652624, Safety and Efficacy of Switching to a FDC of B/F/TAF From E/C/F/TAF, E/C/F/TDF, or ATV+RTV+FTC/TDF in Virologically Suppressed HIV-1 Infected Women 2020. Available from: https://clinicaltrials.gov/ct2/show/NCT02652624."
                    },
                    {
                        "ref-fulltext": "ClinicalTrials.gov. Identifier NCT02603107, Study to Evaluate the Safety and Efficacy of Switching From Regimens Consisting of Boosted Atazanavir or Darunavir Plus Either Emtricitabine/Tenofovir or Abacavir/Lamivudine to Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed HIV-1 Infected Adults 2020. Available from: https://clinicaltrials.gov/ct2/show/NCT02603107.",
                        "@reference-instance-id": "OB2BibRecID-942296673-db9f7bf935437a3a752aafa322248069-23",
                        "@id": "23",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2020"},
                            "ref-website": {"ce:e-address": {
                                "$": "https://clinicaltrials.gov/ct2/show/NCT02603107",
                                "@type": "email"
                            }},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "hiv13386-cit-0023",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85136161851",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-text": "Available from",
                            "ref-authors": {"collaboration": {
                                "@seq": "1",
                                "ce:text": "ClinicalTrials.gov",
                                "ce:indexed-name": "ClinicalTrials.gov"
                            }},
                            "ref-sourcetitle": "Identifier NCT02603107, Study to Evaluate the Safety and Efficacy of Switching From Regimens Consisting of Boosted Atazanavir or Darunavir Plus Either Emtricitabine/Tenofovir or Abacavir/Lamivudine to Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed HIV-1 Infected Adults"
                        },
                        "ce:source-text": "ClinicalTrials.gov. Identifier NCT02603107, Study to Evaluate the Safety and Efficacy of Switching From Regimens Consisting of Boosted Atazanavir or Darunavir Plus Either Emtricitabine/Tenofovir or Abacavir/Lamivudine to Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed HIV-1 Infected Adults 2020. Available from: https://clinicaltrials.gov/ct2/show/NCT02603107."
                    },
                    {
                        "ref-fulltext": "Smith F, Hammerstrom T, Soon G, et al. A meta-analysis to assess the FDA DAVP's TLOVR algorithm in HIV submissions. Drug Inf J. 2011;45(3):291-300.",
                        "@reference-instance-id": "OB2BibRecID-942296673-61d8fc02ad8f2d67d797474f55c37c33-24",
                        "@id": "24",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2011"},
                            "ref-title": {"ref-titletext": "A meta-analysis to assess the FDA DAVP's TLOVR algorithm in HIV submissions"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "hiv13386-cit-0024",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "80051818332",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "45",
                                    "@issue": "3"
                                },
                                "pagerange": {
                                    "@first": "291",
                                    "@last": "300"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "F.",
                                        "@_fa": "true",
                                        "ce:surname": "Smith",
                                        "ce:indexed-name": "Smith F."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "T.",
                                        "@_fa": "true",
                                        "ce:surname": "Hammerstrom",
                                        "ce:indexed-name": "Hammerstrom T."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "G.",
                                        "@_fa": "true",
                                        "ce:surname": "Soon",
                                        "ce:indexed-name": "Soon G."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Drug Inf J"
                        },
                        "ce:source-text": "Smith F, Hammerstrom T, Soon G, et al. A meta-analysis to assess the FDA DAVP's TLOVR algorithm in HIV submissions. Drug Inf J. 2011;45(3):291-300."
                    },
                    {
                        "ref-fulltext": "Surial B, Ledergerber B, Calmy A, et al. Changes in renal function after switching from TDF to TAF in HIV-infected individuals: a prospective cohort study. J Infect Dis. 2020;222:637-645.",
                        "@reference-instance-id": "OB2BibRecID-942296673-8c0a9015aa57b6d5de7ef2692efdddc9-25",
                        "@id": "25",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2020"},
                            "ref-title": {"ref-titletext": "Changes in renal function after switching from TDF to TAF in HIV-infected individuals: a prospective cohort study"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "hiv13386-cit-0025",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85088607429",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {"@volume": "222"},
                                "pagerange": {
                                    "@first": "637",
                                    "@last": "645"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "B.",
                                        "@_fa": "true",
                                        "ce:surname": "Surial",
                                        "ce:indexed-name": "Surial B."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "B.",
                                        "@_fa": "true",
                                        "ce:surname": "Ledergerber",
                                        "ce:indexed-name": "Ledergerber B."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "A.",
                                        "@_fa": "true",
                                        "ce:surname": "Calmy",
                                        "ce:indexed-name": "Calmy A."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "J Infect Dis"
                        },
                        "ce:source-text": "Surial B, Ledergerber B, Calmy A, et al. Changes in renal function after switching from TDF to TAF in HIV-infected individuals: a prospective cohort study. J Infect Dis. 2020;222:637-645."
                    },
                    {
                        "ref-fulltext": "Tungsiripat M, Kitch D, Glesby MJ, et al. A pilot study to determine the impact on dyslipidemia of adding tenofovir to stable background antiretroviral therapy: ACTG 5206. AIDS. 2010;24(11):1781-1784.",
                        "@reference-instance-id": "OB2BibRecID-942296673-60522e3fdf743d67fbc76ff3be3ec163-26",
                        "@id": "26",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2010"},
                            "ref-title": {"ref-titletext": "A pilot study to determine the impact on dyslipidemia of adding tenofovir to stable background antiretroviral therapy: ACTG 5206"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "hiv13386-cit-0026",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "77954319572",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "24",
                                    "@issue": "11"
                                },
                                "pagerange": {
                                    "@first": "1781",
                                    "@last": "1784"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "M.",
                                        "@_fa": "true",
                                        "ce:surname": "Tungsiripat",
                                        "ce:indexed-name": "Tungsiripat M."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "D.",
                                        "@_fa": "true",
                                        "ce:surname": "Kitch",
                                        "ce:indexed-name": "Kitch D."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "M.J.",
                                        "@_fa": "true",
                                        "ce:surname": "Glesby",
                                        "ce:indexed-name": "Glesby M.J."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "AIDS"
                        },
                        "ce:source-text": "Tungsiripat M, Kitch D, Glesby MJ, et al. A pilot study to determine the impact on dyslipidemia of adding tenofovir to stable background antiretroviral therapy: ACTG 5206. AIDS. 2010;24(11):1781-1784."
                    },
                    {
                        "ref-fulltext": "Stellbrink HJ, Lazzarin A, Woolley I, Llibre JM. The potential role of bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) single-tablet regimen in the expanding spectrum of fixed-dose combination therapy for HIV. HIV Med. 2020;21(1):3-16.",
                        "@reference-instance-id": "OB2BibRecID-942296673-0bfa740c3921710de89dd18de861f3af-27",
                        "@id": "27",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2020"},
                            "ref-title": {"ref-titletext": "The potential role of bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) single-tablet regimen in the expanding spectrum of fixed-dose combination therapy for HIV"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "hiv13386-cit-0027",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85078899396",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "21",
                                    "@issue": "1"
                                },
                                "pagerange": {
                                    "@first": "3",
                                    "@last": "16"
                                }
                            },
                            "ref-authors": {"author": [
                                {
                                    "@seq": "1",
                                    "ce:initials": "H.J.",
                                    "@_fa": "true",
                                    "ce:surname": "Stellbrink",
                                    "ce:indexed-name": "Stellbrink H.J."
                                },
                                {
                                    "@seq": "2",
                                    "ce:initials": "A.",
                                    "@_fa": "true",
                                    "ce:surname": "Lazzarin",
                                    "ce:indexed-name": "Lazzarin A."
                                },
                                {
                                    "@seq": "3",
                                    "ce:initials": "I.",
                                    "@_fa": "true",
                                    "ce:surname": "Woolley",
                                    "ce:indexed-name": "Woolley I."
                                },
                                {
                                    "@seq": "4",
                                    "ce:initials": "J.M.",
                                    "@_fa": "true",
                                    "ce:surname": "Llibre",
                                    "ce:indexed-name": "Llibre J.M."
                                }
                            ]},
                            "ref-sourcetitle": "HIV Med"
                        },
                        "ce:source-text": "Stellbrink HJ, Lazzarin A, Woolley I, Llibre JM. The potential role of bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) single-tablet regimen in the expanding spectrum of fixed-dose combination therapy for HIV. HIV Med. 2020;21(1):3-16."
                    },
                    {
                        "ref-fulltext": "Sax PE, Erlandson KM, Lake JE, et al. Weight gain following initiation of antiretroviral therapy: risk factors in randomized comparative clinical trials. Clin Infect Dis. 2020;71(6):1379-1389.",
                        "@reference-instance-id": "OB2BibRecID-942296673-24731e1413496a845dd45d819f3abf0f-28",
                        "@id": "28",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2020"},
                            "ref-title": {"ref-titletext": "Weight gain following initiation of antiretroviral therapy: risk factors in randomized comparative clinical trials"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "hiv13386-cit-0028",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85090910629",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "71",
                                    "@issue": "6"
                                },
                                "pagerange": {
                                    "@first": "1379",
                                    "@last": "1389"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "P.E.",
                                        "@_fa": "true",
                                        "ce:surname": "Sax",
                                        "ce:indexed-name": "Sax P.E."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "K.M.",
                                        "@_fa": "true",
                                        "ce:surname": "Erlandson",
                                        "ce:indexed-name": "Erlandson K.M."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "J.E.",
                                        "@_fa": "true",
                                        "ce:surname": "Lake",
                                        "ce:indexed-name": "Lake J.E."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Clin Infect Dis"
                        },
                        "ce:source-text": "Sax PE, Erlandson KM, Lake JE, et al. Weight gain following initiation of antiretroviral therapy: risk factors in randomized comparative clinical trials. Clin Infect Dis. 2020;71(6):1379-1389."
                    },
                    {
                        "ref-fulltext": "Ando N, Nishijima T, Mizushima D, et al. Long-term weight gain after initiating combination antiretroviral therapy in treatment-naïve Asian people living with human immunodeficiency virus. Int J Infect Dis. 2021;110:21-28.",
                        "@reference-instance-id": "OB2BibRecID-942296673-48d9e7a7f57e35e596ba073c61dff5a4-29",
                        "@id": "29",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2021"},
                            "ref-title": {"ref-titletext": "Long-term weight gain after initiating combination antiretroviral therapy in treatment-naïve Asian people living with human immunodeficiency virus"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "hiv13386-cit-0029",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85111547397",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {"@volume": "110"},
                                "pagerange": {
                                    "@first": "21",
                                    "@last": "28"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "N.",
                                        "@_fa": "true",
                                        "ce:surname": "Ando",
                                        "ce:indexed-name": "Ando N."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "T.",
                                        "@_fa": "true",
                                        "ce:surname": "Nishijima",
                                        "ce:indexed-name": "Nishijima T."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "D.",
                                        "@_fa": "true",
                                        "ce:surname": "Mizushima",
                                        "ce:indexed-name": "Mizushima D."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Int J Infect Dis"
                        },
                        "ce:source-text": "Ando N, Nishijima T, Mizushima D, et al. Long-term weight gain after initiating combination antiretroviral therapy in treatment-naïve Asian people living with human immunodeficiency virus. Int J Infect Dis. 2021;110:21-28."
                    },
                    {
                        "ref-fulltext": "Lake JE, Wu K, Bares SH, et al. Risk factors for weight gain following switch to integrase inhibitor-based antiretroviral therapy. Clin Infect Dis. 2020;71(9):e471-e477.",
                        "@reference-instance-id": "OB2BibRecID-942296673-2cb6b755cad158899ceae7628fe3fdbe-30",
                        "@id": "30",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2020"},
                            "ref-title": {"ref-titletext": "Risk factors for weight gain following switch to integrase inhibitor-based antiretroviral therapy"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "hiv13386-cit-0030",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85097210780",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "71",
                                    "@issue": "9"
                                },
                                "pagerange": {
                                    "@first": "e471",
                                    "@last": "e477"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "J.E.",
                                        "@_fa": "true",
                                        "ce:surname": "Lake",
                                        "ce:indexed-name": "Lake J.E."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "K.",
                                        "@_fa": "true",
                                        "ce:surname": "Wu",
                                        "ce:indexed-name": "Wu K."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "S.H.",
                                        "@_fa": "true",
                                        "ce:surname": "Bares",
                                        "ce:indexed-name": "Bares S.H."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Clin Infect Dis"
                        },
                        "ce:source-text": "Lake JE, Wu K, Bares SH, et al. Risk factors for weight gain following switch to integrase inhibitor-based antiretroviral therapy. Clin Infect Dis. 2020;71(9):e471-e477."
                    },
                    {
                        "ref-fulltext": "Erlandson KM, Carter CC, Melbourne K, et al. Weight change following antiretroviral therapy switch in people with viral suppression: pooled data from randomized clinical trials. Clin Infect Dis. 2021;73:1440-1451.",
                        "@reference-instance-id": "OB2BibRecID-942296673-09681e4ec74dc6e913b82bfa3596e3cd-31",
                        "@id": "31",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2021"},
                            "ref-title": {"ref-titletext": "Weight change following antiretroviral therapy switch in people with viral suppression: pooled data from randomized clinical trials"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "hiv13386-cit-0031",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85110974396",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {"@volume": "73"},
                                "pagerange": {
                                    "@first": "1440",
                                    "@last": "1451"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "K.M.",
                                        "@_fa": "true",
                                        "ce:surname": "Erlandson",
                                        "ce:indexed-name": "Erlandson K.M."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "C.C.",
                                        "@_fa": "true",
                                        "ce:surname": "Carter",
                                        "ce:indexed-name": "Carter C.C."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "K.",
                                        "@_fa": "true",
                                        "ce:surname": "Melbourne",
                                        "ce:indexed-name": "Melbourne K."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Clin Infect Dis"
                        },
                        "ce:source-text": "Erlandson KM, Carter CC, Melbourne K, et al. Weight change following antiretroviral therapy switch in people with viral suppression: pooled data from randomized clinical trials. Clin Infect Dis. 2021;73:1440-1451."
                    },
                    {
                        "ref-fulltext": "Glidden DV, Mulligan K, McMahan V, et al. Metabolic effects of preexposure prophylaxis with coformulated Tenofovir Disoproxil fumarate and emtricitabine. Clin Infect Dis. 2018;67(3):411-419.",
                        "@reference-instance-id": "OB2BibRecID-942296673-afb2c41f820e49426445d5609a5f6b89-32",
                        "@id": "32",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2018"},
                            "ref-title": {"ref-titletext": "Metabolic effects of preexposure prophylaxis with coformulated Tenofovir Disoproxil fumarate and emtricitabine"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "hiv13386-cit-0032",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85048510668",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "67",
                                    "@issue": "3"
                                },
                                "pagerange": {
                                    "@first": "411",
                                    "@last": "419"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "D.V.",
                                        "@_fa": "true",
                                        "ce:surname": "Glidden",
                                        "ce:indexed-name": "Glidden D.V."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "K.",
                                        "@_fa": "true",
                                        "ce:surname": "Mulligan",
                                        "ce:indexed-name": "Mulligan K."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "V.",
                                        "@_fa": "true",
                                        "ce:surname": "McMahan",
                                        "ce:indexed-name": "McMahan V."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Clin Infect Dis"
                        },
                        "ce:source-text": "Glidden DV, Mulligan K, McMahan V, et al. Metabolic effects of preexposure prophylaxis with coformulated Tenofovir Disoproxil fumarate and emtricitabine. Clin Infect Dis. 2018;67(3):411-419."
                    },
                    {
                        "ref-fulltext": "Mayer KH, Molina JM, Thompson MA, et al. Emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis (DISCOVER): primary results from a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial. Lancet. 2020;396(10246):239-254.",
                        "@reference-instance-id": "OB2BibRecID-942296673-2b97c49135b66384127fcb55fe2d8a81-33",
                        "@id": "33",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2020"},
                            "ref-title": {"ref-titletext": "Emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis (DISCOVER): primary results from a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "hiv13386-cit-0033",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85088322381",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {
                                    "@volume": "396",
                                    "@issue": "10246"
                                },
                                "pagerange": {
                                    "@first": "239",
                                    "@last": "254"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "K.H.",
                                        "@_fa": "true",
                                        "ce:surname": "Mayer",
                                        "ce:indexed-name": "Mayer K.H."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "J.M.",
                                        "@_fa": "true",
                                        "ce:surname": "Molina",
                                        "ce:indexed-name": "Molina J.M."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "M.A.",
                                        "@_fa": "true",
                                        "ce:surname": "Thompson",
                                        "ce:indexed-name": "Thompson M.A."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Lancet"
                        },
                        "ce:source-text": "Mayer KH, Molina JM, Thompson MA, et al. Emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis (DISCOVER): primary results from a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial. Lancet. 2020;396(10246):239-254."
                    },
                    {
                        "ref-fulltext": "Griesel R, Maartens G, Chirehwa M, et al. CYP2B6 genotype and weight gain differences between Dolutegravir and Efavirenz. Clin Infect Dis. 2020;73:e3902-e3909.",
                        "@reference-instance-id": "OB2BibRecID-942296673-2a4e3ea0a07dd79b2aa096689fd9360e-34",
                        "@id": "34",
                        "ref-info": {
                            "ref-publicationyear": {"@first": "2020"},
                            "ref-title": {"ref-titletext": "CYP2B6 genotype and weight gain differences between Dolutegravir and Efavirenz"},
                            "refd-itemidlist": {"itemid": [
                                {
                                    "$": "hiv13386-cit-0034",
                                    "@idtype": "FRAGMENTID"
                                },
                                {
                                    "$": "85122546991",
                                    "@idtype": "SGR"
                                }
                            ]},
                            "ref-volisspag": {
                                "voliss": {"@volume": "73"},
                                "pagerange": {
                                    "@first": "e3902",
                                    "@last": "e3909"
                                }
                            },
                            "ref-authors": {
                                "author": [
                                    {
                                        "@seq": "1",
                                        "ce:initials": "R.",
                                        "@_fa": "true",
                                        "ce:surname": "Griesel",
                                        "ce:indexed-name": "Griesel R."
                                    },
                                    {
                                        "@seq": "2",
                                        "ce:initials": "G.",
                                        "@_fa": "true",
                                        "ce:surname": "Maartens",
                                        "ce:indexed-name": "Maartens G."
                                    },
                                    {
                                        "@seq": "3",
                                        "ce:initials": "M.",
                                        "@_fa": "true",
                                        "ce:surname": "Chirehwa",
                                        "ce:indexed-name": "Chirehwa M."
                                    }
                                ],
                                "et-al": null
                            },
                            "ref-sourcetitle": "Clin Infect Dis"
                        },
                        "ce:source-text": "Griesel R, Maartens G, Chirehwa M, et al. CYP2B6 genotype and weight gain differences between Dolutegravir and Efavirenz. Clin Infect Dis. 2020;73:e3902-e3909."
                    }
                ]
            }}
        }
    },
    "affiliation": [
        {
            "affiliation-city": "Bangkok",
            "@id": "60199575",
            "affilname": "Siriraj Hospital",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60199575",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Chaing Mai",
            "@id": "60032250",
            "affilname": "Faculty of Medicine, Chiang Mai University",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60032250",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Khon Kaen",
            "@id": "60026046",
            "affilname": "Faculty of Medicine, Khon Kaen University",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60026046",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Bangkok",
            "@id": "60016965",
            "affilname": "The HIV Netherlands Australia Thailand Research Collaboration",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60016965",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Bangkok",
            "@id": "60015887",
            "affilname": "Faculty of Medicine Ramathibodi Hospital, Mahidol University",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60015887",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Foster City",
            "@id": "60002909",
            "affilname": "Gilead Sciences Incorporated",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60002909",
            "affiliation-country": "United States"
        },
        {
            "affiliation-city": "Bangkok",
            "@id": "60002620",
            "affilname": "Faculty of Medicine, Chulalongkorn University",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60002620",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Taipei",
            "@id": "128478852",
            "affilname": "Gilead Sciences",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/128478852",
            "affiliation-country": "Taiwan"
        },
        {
            "affiliation-city": "Hong Kong",
            "@id": "122211284",
            "affilname": "Gilead Sciences",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/122211284",
            "affiliation-country": "Hong Kong"
        },
        {
            "affiliation-city": "Nontaburi",
            "@id": "106545448",
            "affilname": "Bamrasnaradura Infectious Diseases Institute",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/106545448",
            "affiliation-country": "Thailand"
        }
    ],
    "coredata": {
        "srctype": "j",
        "eid": "2-s2.0-85136240517",
        "dc:description": "Objectives: Data on switching to bictegravir, emtricitabine, and tenofovir alafenamide (B/F/TAF) in virologically suppressed Asian people living with HIV are limited. We performed a pooled analysis of virologically suppressed Asian participants from three international phase III trials to evaluate the efficacy and safety of switching to B/F/TAF. Methods: Virologically suppressed people living with HIV were randomized to switch to B/F/TAF or to stay on baseline regimens. The primary endpoint was the proportion of participants with plasma HIV-1 RNA ≥50 copies/ml at week 48. We analysed the incidence of adverse events (AEs), laboratory abnormalities, and changes in relevant tolerability parameters through 48 weeks. Results: Overall, 136 Asian participants were included. The proportions of participants with plasma HIV-1 RNA ≥50 copies/ml at week 48 were low in both arms (0% for B/F/TAF vs 1.4% for those who stayed on baseline regimens). Those who switched to B/F/TAF had virological suppression rates similar to those who stayed on baseline regimens (100% vs 95.9%, p = 0.2485), with no treatment-emergent resistance. Drug-related AEs occurred in three participants in each arm; none were serious. No participants discontinued the study drug because of AEs, and no deaths were observed. No significant differences were observed between the arms in the median changes in estimated glomerular filtration rate, body weight, and most lipid parameters. Switching from tenofovir disoproxil fumarate-containing regimens to B/F/TAF resulted in a significant decrease in tubular proteinuria compared with those who stayed on baseline regimens (p < 0.01). Conclusions: Virologically suppressed Asian people living with HIV who switched to B/F/TAF maintained 100% virological suppression at week 48, with no treatment-emergent drug resistance and safety profiles comparable to those seen in people who stayed on baseline regimens. Clinical Trial Number: ClinicalTrials.gov (NCT02603120, NCT02652624, and NCT02603107).",
        "pubmed-id": "36912172",
        "prism:coverDate": "2023-03-01",
        "prism:aggregationType": "Journal",
        "prism:url": "https://api.elsevier.com/content/abstract/scopus_id/85136240517",
        "dc:creator": {"author": [{
            "ce:given-name": "Anchalee",
            "preferred-name": {
                "ce:given-name": "Anchalee",
                "ce:initials": "A.",
                "ce:surname": "Avihingsanon",
                "ce:indexed-name": "Avihingsanon A."
            },
            "@seq": "1",
            "ce:initials": "A.",
            "@_fa": "true",
            "affiliation": [
                {
                    "@id": "60016965",
                    "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60016965"
                },
                {
                    "@id": "60002620",
                    "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60002620"
                }
            ],
            "ce:surname": "Avihingsanon",
            "@auid": "57196347321",
            "author-url": "https://api.elsevier.com/content/author/author_id/57196347321",
            "ce:indexed-name": "Avihingsanon A."
        }]},
        "link": [
            {
                "@_fa": "true",
                "@rel": "self",
                "@href": "https://api.elsevier.com/content/abstract/scopus_id/85136240517"
            },
            {
                "@_fa": "true",
                "@rel": "scopus",
                "@href": "https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85136240517&origin=inward"
            },
            {
                "@_fa": "true",
                "@rel": "scopus-citedby",
                "@href": "https://www.scopus.com/inward/citedby.uri?partnerID=HzOxMe3b&scp=85136240517&origin=inward"
            }
        ],
        "source-id": "22307",
        "citedby-count": "0",
        "prism:volume": "24",
        "subtype": "ar",
        "dc:title": "Efficacy and safety of switching to bictegravir, emtricitabine, and tenofovir alafenamide in virologically suppressed Asian adults living with HIV: A pooled analysis from three international phase III randomized trials",
        "openaccess": "1",
        "prism:issn": "14681293 14642662",
        "publishercopyright": "© 2022 The Authors. HIV Medicine published by John Wiley & Sons Ltd on behalf of British HIV Association.",
        "prism:issueIdentifier": "3",
        "subtypeDescription": "Article",
        "prism:publicationName": "HIV Medicine",
        "prism:pageRange": "290-300",
        "prism:endingPage": "300",
        "openaccessFlag": "true",
        "prism:doi": "10.1111/hiv.13386",
        "prism:startingPage": "290",
        "dc:identifier": "SCOPUS_ID:85136240517",
        "dc:publisher": "John Wiley and Sons Inc"
    },
    "idxterms": {"mainterm": [
        {
            "$": "Adenine",
            "@weight": "b",
            "@candidate": "n"
        },
        {
            "$": "Adult",
            "@weight": "b",
            "@candidate": "n"
        },
        {
            "$": "Anti-HIV Agents",
            "@weight": "a",
            "@candidate": "n"
        },
        {
            "$": "Emtricitabine",
            "@weight": "b",
            "@candidate": "n"
        },
        {
            "$": "Heterocyclic Compounds, 4 or More Rings",
            "@weight": "b",
            "@candidate": "n"
        },
        {
            "$": "HIV Infections",
            "@weight": "a",
            "@candidate": "n"
        },
        {
            "$": "Humans",
            "@weight": "b",
            "@candidate": "n"
        },
        {
            "$": "Randomized Controlled Trials as Topic",
            "@weight": "b",
            "@candidate": "n"
        },
        {
            "$": "RNA",
            "@weight": "b",
            "@candidate": "n"
        }
    ]},
    "language": {"@xml:lang": "eng"},
    "authkeywords": {"author-keyword": [
        {
            "@_fa": "true",
            "$": "Asian"
        },
        {
            "@_fa": "true",
            "$": "Bictegravir"
        },
        {
            "@_fa": "true",
            "$": "HIV"
        },
        {
            "@_fa": "true",
            "$": "regimen switch"
        },
        {
            "@_fa": "true",
            "$": "safety"
        },
        {
            "@_fa": "true",
            "$": "virologically suppressed"
        }
    ]},
    "subject-areas": {"subject-area": [
        {
            "@_fa": "true",
            "$": "Health Policy",
            "@code": "2719",
            "@abbrev": "MEDI"
        },
        {
            "@_fa": "true",
            "$": "Infectious Diseases",
            "@code": "2725",
            "@abbrev": "MEDI"
        },
        {
            "@_fa": "true",
            "$": "Pharmacology (medical)",
            "@code": "2736",
            "@abbrev": "MEDI"
        }
    ]},
    "authors": {"author": [
        {
            "ce:given-name": "Anchalee",
            "preferred-name": {
                "ce:given-name": "Anchalee",
                "ce:initials": "A.",
                "ce:surname": "Avihingsanon",
                "ce:indexed-name": "Avihingsanon A."
            },
            "@seq": "1",
            "ce:initials": "A.",
            "@_fa": "true",
            "affiliation": [
                {
                    "@id": "60016965",
                    "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60016965"
                },
                {
                    "@id": "60002620",
                    "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60002620"
                }
            ],
            "ce:surname": "Avihingsanon",
            "@auid": "57196347321",
            "author-url": "https://api.elsevier.com/content/author/author_id/57196347321",
            "ce:indexed-name": "Avihingsanon A."
        },
        {
            "ce:given-name": "Ploenchan",
            "preferred-name": {
                "ce:given-name": "Ploenchan",
                "ce:initials": "P.",
                "ce:surname": "Chetchotisakd",
                "ce:indexed-name": "Chetchotisakd P."
            },
            "@seq": "2",
            "ce:initials": "P.",
            "@_fa": "true",
            "affiliation": {
                "@id": "60026046",
                "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60026046"
            },
            "ce:surname": "Chetchotisakd",
            "@auid": "56992885200",
            "author-url": "https://api.elsevier.com/content/author/author_id/56992885200",
            "ce:indexed-name": "Chetchotisakd P."
        },
        {
            "ce:given-name": "Sasisopin",
            "preferred-name": {
                "ce:given-name": "Sasisopin",
                "ce:initials": "S.",
                "ce:surname": "Kiertiburanakul",
                "ce:indexed-name": "Kiertiburanakul S."
            },
            "@seq": "3",
            "ce:initials": "S.",
            "@_fa": "true",
            "affiliation": {
                "@id": "60015887",
                "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60015887"
            },
            "ce:surname": "Kiertiburanakul",
            "@auid": "6506539792",
            "author-url": "https://api.elsevier.com/content/author/author_id/6506539792",
            "ce:indexed-name": "Kiertiburanakul S."
        },
        {
            "ce:given-name": "Winai",
            "preferred-name": {
                "ce:given-name": "Winai",
                "ce:initials": "W.",
                "ce:surname": "Ratanasuwan",
                "ce:indexed-name": "Ratanasuwan W."
            },
            "@seq": "4",
            "ce:initials": "W.",
            "@_fa": "true",
            "affiliation": {
                "@id": "60199575",
                "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60199575"
            },
            "ce:surname": "Ratanasuwan",
            "@auid": "6602129968",
            "author-url": "https://api.elsevier.com/content/author/author_id/6602129968",
            "ce:indexed-name": "Ratanasuwan W."
        },
        {
            "ce:given-name": "Krittaecho",
            "preferred-name": {
                "ce:given-name": "Krittaecho",
                "ce:initials": "K.",
                "ce:surname": "Siripassorn",
                "ce:indexed-name": "Siripassorn K."
            },
            "@seq": "5",
            "ce:initials": "K.",
            "@_fa": "true",
            "affiliation": {
                "@id": "106545448",
                "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/106545448"
            },
            "ce:surname": "Siripassorn",
            "@auid": "35559614900",
            "author-url": "https://api.elsevier.com/content/author/author_id/35559614900",
            "ce:indexed-name": "Siripassorn K."
        },
        {
            "ce:given-name": "Khuanchai",
            "preferred-name": {
                "ce:given-name": "Khuanchai",
                "ce:initials": "K.",
                "ce:surname": "Supparatpinyo",
                "ce:indexed-name": "Supparatpinyo K."
            },
            "@seq": "6",
            "ce:initials": "K.",
            "@_fa": "true",
            "affiliation": {
                "@id": "60032250",
                "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60032250"
            },
            "ce:surname": "Supparatpinyo",
            "@auid": "6602542079",
            "author-url": "https://api.elsevier.com/content/author/author_id/6602542079",
            "ce:indexed-name": "Supparatpinyo K."
        },
        {
            "ce:given-name": "Hal",
            "preferred-name": {
                "ce:given-name": "Hal",
                "ce:initials": "H.",
                "ce:surname": "Martin",
                "ce:indexed-name": "Martin H."
            },
            "@seq": "7",
            "ce:initials": "H.",
            "@_fa": "true",
            "affiliation": {
                "@id": "60002909",
                "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60002909"
            },
            "ce:surname": "Martin",
            "@auid": "56173399700",
            "author-url": "https://api.elsevier.com/content/author/author_id/56173399700",
            "ce:indexed-name": "Martin H."
        },
        {
            "ce:given-name": "Hui",
            "preferred-name": {
                "ce:given-name": "Hui",
                "ce:initials": "H.",
                "ce:surname": "Wang",
                "ce:indexed-name": "Wang H."
            },
            "@seq": "8",
            "ce:initials": "H.",
            "@_fa": "true",
            "affiliation": {
                "@id": "60002909",
                "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60002909"
            },
            "ce:surname": "Wang",
            "@auid": "57196428615",
            "author-url": "https://api.elsevier.com/content/author/author_id/57196428615",
            "ce:indexed-name": "Wang H."
        },
        {
            "ce:given-name": "TinHung",
            "preferred-name": {
                "ce:given-name": "Tin Hung",
                "ce:initials": "T.H.",
                "ce:surname": "Wong",
                "ce:indexed-name": "Wong T.H."
            },
            "@seq": "9",
            "ce:initials": "T.",
            "@_fa": "true",
            "affiliation": {
                "@id": "122211284",
                "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/122211284"
            },
            "ce:surname": "Wong",
            "@auid": "57269830800",
            "author-url": "https://api.elsevier.com/content/author/author_id/57269830800",
            "ce:indexed-name": "Wong T."
        },
        {
            "ce:given-name": "Hsiu Yin",
            "preferred-name": {
                "ce:given-name": "Hsiu Yin",
                "ce:initials": "H.Y.",
                "ce:surname": "Wang",
                "ce:indexed-name": "Wang H.Y."
            },
            "@seq": "10",
            "ce:initials": "H.Y.",
            "@_fa": "true",
            "affiliation": {
                "@id": "128478852",
                "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/128478852"
            },
            "ce:surname": "Wang",
            "@auid": "57850377200",
            "author-url": "https://api.elsevier.com/content/author/author_id/57850377200",
            "ce:indexed-name": "Wang H.Y."
        }
    ]}
}}